The FSCN1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Homo sapiens Raji B lymphocyte cell line, designed for targeted disruption of the FSCN1 gene. This polyclonal pool offers a heterogeneous loss-of-function model for studying fascin-dependent processes without clonal selection, providing a versatile tool for functional genomics and phenotypic analyses in a lymphoid background.
The Raji host cell line is an Epstein-Barr virus (EBV)-positive Burkitt’s lymphoma-derived B cell model widely employed in immunology and oncology research. These cells exhibit robust proliferation and retain key B cell characteristics, including antigen presentation capabilities and immunoglobulin expression, making them particularly suitable for investigating lymphocyte signaling, immune response, and hematological malignancy progression.
FSCN1 encodes fascin, an actin-bundling protein essential for filopodia formation and cell migration. Fascin is regulated transcriptionally by STAT3, NF-??B, ??-catenin/TCF, and TGF-?? signaling pathways, and its activity is modulated through interactions with PKC, L-plastin, cortactin, and actin itself. Downstream, fascin promotes cell invasion and matrix metalloproteinase expression, with functional integration into Rac1 and Cdc42-mediated cytoskeletal rearrangements. Disruption of FSCN1 thus abolishes the bundling of actin filaments, leading to impaired protrusion dynamics, reduced adhesion turnover, and diminished invasive capacity.
In the Raji B lymphocyte context, FSCN1 knockout uniquely models the intersection of cytoskeletal regulation and immune cell migration. Fascin is implicated in lymphocyte homing and trafficking, and its loss in this EBV-transformed background may alter cell dissemination patterns relevant to lymphoma biology. By eliminating the actin-bundling function, this knockout enables dissection of fascin’s role in B cell adhesion, motility, and potential contribution to metastasis-like behavior in hematologic malignancies.
This polyclonal knockout population is ideally suited for cancer metastasis research, particularly mechanistic studies on cell migration and invasion, cytoskeletal dynamics, and the evaluation of fascin as a therapeutic target. Researchers can employ standard assays such as western blotting, immunofluorescence, transwell migration/invasion assays, cell adhesion assays, flow cytometry, RNA-seq, and phospho-signaling analysis to characterize the impact of FSCN1 loss on downstream pathways. Its application extends to drug target validation for fascin inhibitors in lymphoma and other tumors where FSCN1 overexpression correlates with poor prognosis. For additional details, contact Ascent Research.
